Literature DB >> 9834741

Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives.

N J Lowe1.   

Abstract

BACKGROUND: Botulinum A toxin has been well documented as a successful treatment for hyperfunctional upper facial expression lines. Currently, there are two commercial sources for botulinum toxin--Botox and Dysport. Only Botox is currently available in the United States; however, both Botox and Dysport are available in a number of European and other countries.
OBJECTIVES: There are several differences between these two sources of botulinum toxin, including different potency of their dosage units. This article will review the uses of these two sources of botulinum toxin and discuss the dilution and dosing of botulinum toxin for facial expression lines.
RESULTS: One unit of Botox is approximately equivalent in potency to 4 U of Dysport.
CONCLUSIONS: Both commercial types of botulinum toxin can be used interchangeably with appropriate dosage selection.

Mesh:

Substances:

Year:  1998        PMID: 9834741     DOI: 10.1111/j.1524-4725.1998.tb04100.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  2 in total

1.  Botulinum toxin type A for the management of glabellar rhytids.

Authors:  Anne Marie Tremaine; Jerry L McCullough
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-04-07

Review 2.  Role of Botulinum Toxin Type-A (BTX-A) in the Management of Trigeminal Neuralgia.

Authors:  Gaurav Verma
Journal:  Pain Res Treat       Date:  2013-10-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.